Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.

Sagara, Hironori; Barbier, Nathalie; Ishii, Tsuyoshi; Yoshisue, Hajime; Nikolaev, Ivan; Hosoe, Motoi; Gon, Yasuhiro

Sagara, Hironori; Barbier, Nathalie; Ishii, Tsuyoshi; Yoshisue, Hajime; Nikolaev, Ivan; Hosoe, Motoi; Gon, Yasuhiro.

Afiliação

Sagara H; Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University, School of Medicine, Shinagawa-ku, Tokyo, Japan sagarah@med.showa-u.ac.jp.
Barbier N; Novartis Pharma AG, Basel, Switzerland.
Ishii T; Novartis Pharma KK, Minato-ku, Tokyo, Japan.
Yoshisue H; Novartis Pharma KK, Minato-ku, Tokyo, Japan.
Nikolaev I; Novartis Pharma AG, Basel, Switzerland.
Hosoe M; Novartis Pharma AG, Basel, Switzerland.
Gon Y; Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.

BMJ Open Respir Res ; 8(1)2021 03.

Article em En | MEDLINE | ID: mdl-33737310

Assuntos

Asma; Glicopirrolato; Asma/tratamento farmacológico; Combinação de Medicamentos; Humanos; Indanos; Irídio; Furoato de Mometasona; Nebulizadores e Vaporizadores; Quinolonas

Palavras-chave

asthma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Glicopirrolato Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BMJ Open Respir Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google